Clinical trial
Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT…
NCT00144976 · Institut Claudius Regaud, Other · Completed
Key facts
| NCT number | NCT00144976 |
|---|---|
| Title | Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma |
| Official title | Pilot Study, Without Direct Individual Benefice, of Biological Effect of Tarceva (OSI-774) at Posology of 150 mg by Day for Patients Stricken by ENT Epidermoid Carcinoma Waiting for First Surgical Picking up. |
| Lead sponsor | Institut Claudius Regaud, Other |
| Collaborators | Roche Pharma AG Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Head and Neck Neoplasms |
| Intervention type | Drug |
| Interventions | Tarceva |
| Enrollment | 43 |
| Start date | Oct 1, 2003 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Sep 5, 2005 |
| Last update posted | Mar 27, 2015 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: